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Introduction
Considerable advances in coronary stent designs and deliv-
ery systems have prompted a growing number of interven-
tional cardiologists to attempt the implantation of stents
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AIMS: This study examined the six-month
angiographic results of direct coronary
stenting, and compared the nine-month
safety, efficacy and cost of this strategy
versus stenting after balloon predilata-
tion.
METHODS: In phase I of VELVET, 122
patients (mean age = 62.3 ± 10.1 years,
77% male, 11% with diabetes) with
angina pectoris or myocardial ischemia
resulting from a single de novo 51% to
95% coronary stenosis underwent direct
stenting. The endpoints of phase I
included angiographic findings and rates
of major adverse cardiac events up to six
months of follow-up. In phase II, 401
patients (mean age = 61.3 ± 10.8 years,
79% male, 16% with diabetes) with
angina pectoris or documented myocar-
dial ischemia resulting from single or mul-
tiple, de novo or restenotic, coronary
lesions were randomized between direct
stenting and stenting after predilatation.
The immediate angiographic results, and
clinical outcomes and costs associated
with the two treatment strategies up to
nine months of follow-up were com-
pared.
RESULTS: In phase I the mean diameter
stenosis immediately before and after the
procedure, and at six months was
61.7±9.4%, 13.5±6.3%, and 33.6±16.2%,
respectively. The six-month binary
restenosis rate was 11%. The overall rate
of major adverse cardiac events, including
two non-cardiac deaths, was 9.8%. In
phase II, the success rates of the
intended delivery strategies were 87.9%
and 97.9% for direct stenting and predi-
latation, respectively (p < 0.001), while
the procedural success rates were similar
(93.9% vs 96.5%). Over a follow-up
period of nine months, major adverse
cardiac events rates were 12.0% and
10.9% in patients randomized to direct
stenting and predilatation, respectively
(non-significant). Analyses of the costs
incurred up to nine months in each treat-
ment group revealed a mean saving of
e362 per patient in favor of the direct
stenting strategy (non-significant).
CONCLUSIONS: Compared with a strategy
of stenting preceded by balloon dilata-
tion, direct stenting was associated with
an equivalent procedural success rate,
equivalent clinical results up to nine
months of follow-up, and a reduction in
procedural and in-hospital costs
(p < 0.0001 and p < 0.001, respectively),
that was no longer significant after nine
months. (Int J Cardiovasc Intervent 2003; 5:
17–26)
Keywords: coronary stent – direct stenting – predilatation - angioplasty –
restenosis - coronary artery disease
without prior balloon dilatation of the coronary lesion.1–11
Besides the likelihood of saving cost and time, this strategy
offers the hypothetical advantages of causing less injury
and less endothelial denudation by immediate scaffolding
of the vessel wall, thereby facilitating re-endothelializa-
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tion. On the other hand, the direct and forceful implanta-
tion of the stent through the stenosis may be considerably
more traumatic than its insertion after balloon predilata-
tion. The ultimate balance of these opposing effects of
direct stenting can only be reliably addressed by properly
designed clinical trials. In recent randomized studies in
patients with or without acute myocardial infarction,
direct coronary stenting, though sometimes limited by
high lesion complexity, has generally been found to be
safe and effective, and associated with the use of fewer
devices during the procedure, and shorter duration of pro-
cedures.1,3,6,9,11–17 Few studies, however, have separately
examined the short- and long-term angiographic, clinical
and economic results of direct coronary stenting.
The first objective of this study was to compare the
safety and efficacy of direct stenting versus the delivery of a
new balloon-expandable stent mounted on a rapid
exchange delivery system preceded by dilatation of native
coronary artery lesions. The second objective was to
compare the medical resource consumption and costs
incurred with each treatment method. 
Patient population and methods
This multicenter trial enrolled 523 patients with athero-
sclerotic disease of native coronary arteries between April
2000 and December 2000. A list of participating investiga-
tors from ten European countries and the number of
patients enrolled at each medical center is presented in the
Appendix. The study was conducted in two phases. 
Phase I was non-randomized and included 122 patients
with single, de novo coronary stenoses of 51% to 95%,
≤15 mm in length in vessels ≥3.0 to 4.0 mm in diameter,
who underwent direct stenting with the Bx VELOCITY™
balloon-expandable stent (Cordis Corp., Johnson &
Johnson, Warren, NJ, USA). This six-month registry was
designed to familiarize the operators with the use of the
stent and its delivery system. It also provided an opportu-
nity to measure the six-month performance of the Bx
VELOCITY™ stent by quantitative coronary angiography.
Its endpoints included: (1) incidence of major adverse
cardiac events and cerebrovascular accidents up to 30 days,
or symptomatic ischemia at the one-month visit (primary
endpoint), and major adverse cardiac events up to six
months after the index procedure; and (2) angiographic
findings at the time of the procedure and after six months
by quantitative coronary analysis.  Major adverse cardiac
events were defined as death from all causes, myocardial
infarction, coronary artery bypass grafting, and further per-
cutaneous target lesion interventions. 
In phase II, 401 patients were randomized between direct
stenting and stenting preceded by dilatation of single or
multiple 51% to 95% de novo or restenotic lesion(s)
≤30 mm in length and 2.25 mm to 4.0 mm in diameter,
which could be covered by one or two stents; these patients
were followed clinically for nine months after the index pro-
cedure, without the confounding effect of protocol-man-
dated follow-up angiography. Its endpoints included: (1)
incidence of major adverse cardiac events and cerebrovascu-
lar accidents up to 30 days or symptomatic ischemia at the
one-month visit (primary endpoint), and major adverse
cardiac events at nine months after the index procedure; (2)
angiographic findings at the time of the procedure; and (3)
medical costs and cost-effectiveness up to nine months after
the index procedure. The definition of major adverse cardiac
events in phase II was the same as indicated earlier, except
for target vessel in place of target lesion interventions. Deliv-
ery strategy success was defined as the successful implanta-
tion of the study stent using the assigned treatment strategy,
and achievement of < 30% diameter stenosis by quantitative
coronary analysis. Procedural success was defined as suc-
cessful implantation of the study stent, achievement of
< 30% diameter stenosis by quantitative coronary analysis,
and freedom from in-hospital major adverse cardiac events.
This study was approved by the Ethical Review Commit-
tees of all participating medical centers, and written
informed consent was obtained from all patients. In both
phases of the study, eligible patients were between 18 and
85 years of age and had stable angina or Braunwald Class
B and C, I-II-III unstable angina,18 or otherwise docu-
mented myocardial ischemia. The clinical exclusion crite-
ria for both phases were: residual enzyme elevation from
myocardial infarction within 72 h, intervention on other
lesions within the preceding 30 days, unstable angina
Braunwald Class A, I-II-III, a left ventricular ejection frac-
tion ≤ 30%, serum creatinine > 3.0 mg/dl, chronic warfarin
anticoagulation, and allergies to aspirin, clopidrogel, ticlo-
pidine or heparin. Procedural or angiographic exclusion
criteria included unprotected left main coronary disease
with ≥50% stenosis, pretreatment with a device other than
an angioplasty balloon, stenting in saphenous vein grafts,
in-stent restenosis, thrombi causing ≥50% stenosis within
target lesion, TIMI grade 0 flow, a target lesion located at a
bifurcation and requiring side branch stenting, > 50%
stenosis proximal or distal to the target lesion treated
during the same procedure, and the presence of a pre-exis-
tent stent within 5 mm of the target lesion. 
Randomization procedure
Following catheterization and identification of an eligible
target lesion, patients were randomized by the data
coordinating center, after the investigator obtained
informed consent and verification of all eligibility criteria.
Stents and delivery system, and procedural
characteristics
In phase I, only 18 mm stents were available with diame-
ters ranging from 2.5 mm to 4.0 mm, in increments of
0.25 mm. In phase II, investigators had a choice of stents
that were 8 mm to 33 mm in length, in increments of
5 mm, with diameters ranging from 2.5 mm to 4.0 mm, in
increments of 0.25 mm. The stents were mounted and
crimped on the Raptor™ rapid exchange delivery system
(Cordis Corp.). Guiding catheters with an inner lumen
diameter ≥0.064” were recommended for all procedures.
18 P Serruys, S IJsselmuiden, B van Hout, et al
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Percutaneous introduction of the guiding catheters and
revascularizing devices, and predilatation procedures were
performed according to standard procedures for each
participating center, and remained unchanged throughout
the study.
Peri- and postprocedural long-term drug therapy
Aspirin 325 mg daily was administered at least once before
the index procedure, and continued indefinitely thereafter.
Heparin was administered during the procedure to main-
tain an activated clotting time > 250 sec, and discontinued
within 12 h after the procedure. The use of glycoprotein
IIb/IIIa inhibitors was left to the operator’s discretion.
Clopidogrel in a loading dose of 300 mg followed by
75 mg daily, or ticlopidine 250 mg twice daily, were begun
before the procedure. Clopidogrel was continued in doses
of 75 mg once daily, and ticlopidine in doses of 250 mg
twice daily, each for four weeks.
Patient follow-up
Patients returned at 30 days and six months (those
enrolled in phases I and II), and at nine months (those
enrolled in phase II), for a physical examination, assess-
ment of anginal status according to the Canadian Cardio-
vascular Society classification,19 and recording of interim
major adverse cardiac clinical events or coronary interven-
tions. A 12-lead electrocardiogram was recorded at these
visits, as well as other non-invasive tests if clinically indi-
cated. Patients enrolled in phase I also underwent six-
month follow-up angiography for quantitative coronary
analysis. The six-month angiograms were waived in
patients who had undergone an earlier unscheduled angio-
graphic examination for clinical reasons.
Quantitative coronary angiography
All angiograms obtained during the index procedure in
both patient groups, and at six months in patients enrolled
in phase I, were analyzed by an independent core labora-
tory (Cardialysis, Rotterdam, The Netherlands). The mea-
surements included assessment of TIMI flow grade,
presence of thrombus, lesion length, eccentricity, and cal-
cification, American Heart Association/American College
of Cardiology class, and dissection grade. Restenosis was
defined as a luminal narrowing ≥50% at six months in
phase I patients. Minimal luminal diameter and % dia-
meter stenosis (%DS) were measured both ‘in-stent’, i.e.
within the stent borders, and ‘in-segment’, i.e. within the
vessel segment defined by side branches bounding the
stented segment. All unscheduled angiograms prompted
by return of symptoms, abnormal stress testing, or other
untoward coronary events, were also submitted to Cardial-
ysis for quantitative coronary analysis.
Cost analysis
Collection of costs and cost effectiveness data was limited
to direct medical costs. Comparisons of resource utiliza-
tion between the two treatment strategies included costs of
the initial procedure, and resources used until discharge
from the hospital and up to nine months of follow-up in
phase II. The primary goal of the economic evaluation was
to assess the probability that direct stenting combines
added effectiveness with cost savings compared to stenting
with predilatation. Additional assessments included the
probability that direct stenting is less effective though less
costly, more effective and more costly, or less effective and
more costly than stenting and predilatation.
Safety, events and data monitoring
A Data and Safety Monitoring Board reviewed the data to
identify any potential safety issues.  Members of this Board
were not affiliated with the study sponsor. An Endpoint
Review Committee comprising two independent physi-
cians and one VELVET investigator adjudicated and con-
firmed the classification of major adverse cardiac events
and cerebrovascular events. 
Statistical analyses
An enrolment of 520 patients was planned for this study.
Ultimately, 122 patients were included in phase I, and 401
were randomized in phase II. This latter sample size was
expected to detect a minimum treatment difference of 9%
in the primary endpoint with an 80% power, including a
10% loss to follow-up, and a two-sided significance level
set at 0.05. All efficacy and safety analyses were performed
on an intention-to-treat basis. 
Efficacy analysis in phase II  
The proportion of patients who reached a 30-day primary
endpoint was calculated in each treatment group and
tested for equivalence by the Farrington-Manning
method.20 Quantitative angiographic results from the core
laboratory were summarized for each treatment group and
time point. Between-groups comparisons were performed
by one-way analysis of variance. 
Safety analysis in phase II
All major adverse cardiac events occurring in each treat-
ment group before hospital discharge, and at 30 days and
nine months after the index procedure, were counted and
presented in a hierarchical order. The Kaplan-Meier life-
table method was used to analyze time to clinical events.
Comparisons of the event-free survival curves in the two
phase II treatment groups were made using the Wilcoxon
and log-rank tests at nine months’ follow-up. 
Costs in each treatment group were calculated by multi-
plying resource utilization with unit costs from the Nether-
lands. Differences in costs were compared by Student’s
t-test and Wilcoxon rank order statistic. The probability of
both difference in costs and difference in effects being in
the four quadrants of the cost-effectiveness plane was
assessed by calculating (by a Gaussian method) the appro-
Direct stenting versus predilatation 19
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priate densities, using the bivariate normal distribution of
both average costs and average effects.
All computations were performed with the SAS® (SAS
Institute) and EquivTest (Statistical Solutions) software
packages. Values are presented as mean±standard devia-
tion (SD). A two-sided p value < 0.05 was considered sta-
tistically significant. 
Results
Phase I
The baseline characteristics of the 122 patients enrolled in
phase I of VELVET are presented in Table 1. The overall
success of the intended treatment strategy was 91.8%, and
the ultimate procedural success rate was 95.1%. The main
cause of delivery strategy failure was the need for predilata-
tion in 8.2% of patients, because of failure of the stent
device to cross the lesion in 7.4% of cases. However, all Bx
VELOCITY™ stents were successfully withdrawn after the
direct stenting attempt. 
The mean duration of hospitalization for the index pro-
cedure was 2.5±1.2 days. The angiographic follow-up at
six months included 99 of the 122 patients (81%). Causes
for missing follow-up angiograms included death (n=2),
and patient refusal (n=21). Table 2 presents the angio-
graphic measurements performed immediately before and
after the index procedure, and at six months. The resteno-
sis rate among 99 patients who underwent follow-up
angiography at six months was 11%. 
Early and long-term clinical events 
At a mean follow-up of 37±17 days, stable (n=4) or
unstable (n=2) angina had returned in 5% of 120 patients
who could be analyzed (Table 2). Table 2 also lists the
numbers of major adverse cardiac events (including two
non-cardiac deaths) recorded between the index procedure
and 180 days. One patient died of rapidly evolving lung
carcinoma at 110 days, and the other of profound ticlopi-
dine-induced thrombocytopenia at 23 days. The overall
proportion of patients free from major adverse cardiac
events and free from target lesion revascularization at six
months in phase I was 90.2% and 93.4%, respectively. By
multivariate analysis, among 34 demographic, clinical and
angiographic variables tested, type IIb eccentricity of the
lesion (odds ratio 8.05, p=0.055) and minimum luminal
diameter after stent implantation (odds ratio 0.131,
p=0.053) were independent predictors of major adverse
cardiac events, and having more than one stent implanted
(odds ratio 85.97, p=0.006), hypercholesterolemia (odds
ratio 16.96, p=0.005), and minimum luminal diameter
after stent implantation (odds ratio 0.007, p=0.01) were
independent predictors of restenosis. 
Phase II
The baseline characteristics of the 401 patients enrolled in
phase II of VELVET, and of each treatment group sepa-
rately, are presented in Table 3. There was no difference
between the two treatment groups. The mean duration of
hospitalization for the index procedure was 2.6±1.8 days
(range 2–24) in the predilated group, versus 2.7±2.5 days
(range 1–33) in the directly stented group. The success of
the intended delivery strategy per lesion treated was 97.9%
for predilatation versus 87.9% for direct stenting
(p < 0.001), while the procedural success rates per patient
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Age, y (mean ± SD) 62.3 ± 10.1
Male/female 77/23
Diabetics 11
Previous/current smoking history 42/25
Treated hypercholesterolemia 49
Treated hypertension 53
Previous myocardial infarction/coronary surgery/angioplasty 34/2/17
Braunwald classes I/II/III unstable angina pectoris 16/21/12
Canadian Cardiovascular Society classes I/II/III/IV stable angina pectoris 4/21/10/1
Silent ischemia 12
Number of diseased coronary arteries:
1 68
2 21
3 11
Reference vessel diameter, mm (mean±SD, range) 2.80±0.56, 1.85–4.45
Lesion length, mm (mean±SD, range) 10.25±3.64, 3.40–24.17
Lesion location:
right coronary artery 31
left anterior descending artery 50
left circumflex artery 19
Unless otherwise indicated, values are percentages of 122 patients.
Table 1
Baseline characteristics of 122 patients enrolled in phase I of VELVET.
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treated were similar (96.5% vs 93.9%). The main reason
for the significant difference in the success rates of the
intended strategy between the two groups was the need to
predilate 22 of 240 (9.2%) treated lesions in the direct
stenting group. The results of quantitative coronary analy-
sis after the index procedure in the two randomized
groups are shown in Table 4. Except for a slightly greater
in-stent %DS in the direct stenting group (p < 0.02), no sig-
nificant difference was observed between the two groups
in the immediate angiographic outcomes. The cumulative
distribution of postprocedural in-stent %DS in each treat-
ment group is shown in Figure 1. Coronary artery dissec-
tions occurred in 8.7% of direct stenting procedures, com-
pared with 25.8% of procedures preceded by balloon
dilatation (p < 0.001).
By multivariate analysis of the results in the direct stent-
ing group, dissection at the treated site during attempted
direct stenting (odds ratio 0.182, p = 0.026), younger age
(odds ratio 0.945, p = 0.012), and a history of previous
coronary artery bypass graft (odds ratio 0.206, p = 0.016)
were independent negative predictors of direct stenting
strategy success.
Direct stenting versus predilatation 21
Measurement (n=number of observations available for analysis) p-value
Reference vessel diameter, mm (n):
before procedure 2.80±0.56 (122) –
after procedure 2.95±0.46 (121) 0.0001
six months 2.79±0.62 (97) 0.672
MLD, mm (n):
before procedure 1.06±0.34 (122) –
after procedure 2.55±0.41 (121) 0.0001
six months 1.85±0.60 (99) 0.0001
Percent diameter stenosis (n):
before procedure 61.7±9.4 (122) –
after procedure 13.5±6.3 (121) 0.0001
six months 33.6±16.2 (99) 0.0001
Immediate gain, mm (n) 1.48±0.40 (121) –
Late loss, mm (n) 0.70±0.43 (99) –
Total occlusion, % (n) 2 (99) –
Binary restenosis rate, % (n) 11 (99) –
Adverse events (hierarchical order) n (% of patients)
0–30 DAYS CLINICAL EVENTS:
Death: 1 (0.8)
Cardiac 0
Non-cardiac 1 (0.8)
Cerebrovascular accident 0 (0)
Myocardial infarction: 3 (2.5)
Q-wave 1 (0.8)
non-Q-wave 2 (1.6)
Coronary bypass surgery 0
Percutaneous target lesion revascularization 1 (0.8)
Symptomatic ischemia 6 (5.0)
Major adverse cardiac and cerebrovascular events 5 (4.1)
OVERALL PRIMARY ENDPOINT* 11 (9.1)
0–180 DAYS MACE:
Death: 2 (1.6)
Cardiac 0
Non-cardiac 2 (1.6)
Myocardial infarction: 4 (3.3)
Q-wave 1 (0.8)
non-Q-wave 3 (2.5)
Coronary bypass surgery 3 (2.5)
Percutaneous target lesion revascularization 3 (2.5)
OVERALL MACE 12 (9.8)
*Primary endpoint phase I=symptomatic ischemia at the one-month visit or major adverse cardiac events and cerebrovascular accidents at 30 days. MLD=minimal
luminal diameter. p values refer to comparisons with measurements before procedure. MACE=major adverse cardiac events.
Table 2
Results of quantitative coronary analysis and major adverse events at 1 month and 6 months in 122 phase I patients.
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One-month clinical results
At a mean of 38±25 days after the index procedure, stable
and unstable angina had returned in 6.1% and 1.5%,
respectively, of 196 patients randomized to predilation,
versus 5.7% and 2.1%, respectively, of 192 patients ran-
domized to direct stenting (non-significant). Likewise, no
difference was found between the two groups in overall
rates of major adverse cardiac events and cerebrovascular
events at one month (3.0% in both groups, Table 4). Two
patients randomized to predilatation died out of hospital,
one due to presumed stent thrombosis three days after the
index procedure, and the other due to cerebrovascular acci-
dent 25 days after the index procedure. One patient ran-
domized to direct stenting died of presumed stent
thrombosis 28 days after the index procedure.
By multivariate analysis of the results in the overall
population, male gender (odds ratio 0.323, p < 0.001),
unstable angina (odds ratio 2.526, p = 0.005), history of
coronary artery bypass graft (odds ratio 4.154, p = 0.015
and having more than one stent implanted (odds ratio
3.442, p = 0.01), were independent predictors of recurrent
ischemic events at the one-month visit, or major adverse
cardiac events and cerebrovascular accidents at 30 days.
Long-term adverse clinical events 
At 270 days after the index procedure, major adverse
cardiac events had occurred in 24 of 200 (12.0%) patients
randomized to direct stenting, versus 22 of 201 (10.9%)
patients randomized to predilatation (non-significant,
Table 4). One patient randomized to direct stenting died
of acute thrombotic occlusion in a non-target vessel after
an intracoronary ultrasound examination, 269 days after
the index procedure. The cumulative survival free from
target vessel revascularization in each patient group is pre-
sented in Figure 2A, and the major adverse cardiac event-
free survival is shown in Figure 2B. Neither analysis
showed a difference between the two groups.
Cost analysis
The mean procedural, hospitalization and long-term costs
calculated per patient in each treatment group are listed in
Table 5. The mean overall procedural cost per patient was
22 P Serruys, S IJsselmuiden, B van Hout, et al
Characteristic Direct stenting Predilated All patients
(n = 200) (n = 201) (n = 401)
243 lesions 240 lesions 483 lesions
Age, y (mean±SD) 61.4±11.1 61.1±10.5 61.3±10.8
Male/female 82/18 77/23 79/21
Diabetics 17 15 16
Previous/current smoking history 37/34 35/29 36/31
Treated hypercholesterolemia 48 45 46
Treated hypertension 54 57 56
Previous MI/CABG/angioplasty 46/6/21 36/3/12 41/4/17
Braunwald classes I/II/III unstable AP 10/24/14 9/22/15 10/23/15
CCS classes I/II/III/IV stable AP 4/22/11/1 5/27/9/0 4/24/10/1
Silent ischemia 10 10 10
Number of diseased coronary arteries:
1 58 57 58
2 28 29 29
3 14 14 14
# of lesions/patient (mean±SD) 1.2±0.5 1.2±0.5 1.2±0.5
Lesion location:
right coronary artery 28 30 29
left anterior descending artery 42 46 44
left circumflex artery 29 24 27
Preprocedural TIMI grade:
0 0 0 0
I 1 2 2
II 18 11 14
III 81 87 84
ACC/AHA lesion classification:
type A 5 5 5
type B1 36 31 34
type B2 55 62 59
type C 3 2 2
MI=myocardial infarction; CABG=coronary artery bypass graft; AP=angina pectoris; CCS=Canadian Cardiovascular Society; ACC/AHA=American College of
Cardiology/American Heart Association
Unless otherwise indicated, values are percentages of patients or lesions.
Table 3
Baseline characteristics of patients randomized in phase II of VELVET.
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Direct stenting versus predilatation 23
Quantitative angiographic analysis Direct stenting (n = 200) Predilated (n = 201)
243 lesions 240 lesion
Reference vessel diameter, mm (mean±SD) 2.83±0.47 2.86±0.49
In-stent % diameter stenosis* (mean±SD) 13.9±6.8 12.5±6.3
In-segment % diameter stenosis (mean±SD) 25.1±10.1 24.4±10.2
In-stent MLD, mm (mean±SD) 2.43±0.43 2.49±0.43
In-segment MLD (mean±SD) 2.05±0.48 2.06±0.49
Adverse events (hierarchical order) Direct stenting Predilated 
0–30 DAYS:
Death: 1 (0.5) 2 (1.0)
Cardiac 1 (0.5) 1 (0.5)
Non-cardiac 0 1 (0.5)
Cerebrovascular accident 0 0
Myocardial infarction: 4 (2.0) 4 (2.0)
Q-wave 1 (0.5) 1 (0.5)
non Q-wave 3 (1.5) 3 (1.5)
Coronary bypass surgery 0 0
Percutaneous target vessel revascularization 1 (0.5) 0
Symptomatic ischemia 12 (6.3) 14 (7.1)
Major adverse cardiac and cerebrovascular events 6 (3.0) 6 (3.0)
OVERALL PRIMARY ENDPOINT** 18 (9.3) 20 (10.1)
0–270 DAYS:
Death: 2 (1.0) 2 (1.0)
Cardiac 2 (1.0) 1 (0.5)
Non-cardiac 0 1 (0.5)
Myocardial infarction: 8 (4.0) 7 (3.5)
Q-wave 2 (1.0) 3 (1.5)
non Q-wave 6 (3.0) 4 (2.0)
Coronary artery bypass graft surgery 3 (1.5) 1 (0.5)
Percutaneous target vessel revascularization 11 (5.5) 12 (6.0)
OVERALL MACE 24 (12.0) 22 (10.9)
Unless indicated otherwise, values represent numbers (%) of patients. * p < 0.05. ** Primary endpoint phase II=symptomatic ischemia at the one-month visit or major
adverse cardiac events and cerebrovascular accidents at 30 days. MLD=minimal luminal diameter; MACE=major adverse cardiac events.
Table 4
Results of postprocedural quantitative coronary angiographic analysis, and major adverse events up to one month and nine months in 200 patients random-
ized to direct stenting and 201 patients randomized to stenting preceded by balloon angioplasty.
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Figure 1
Cumulative distribution of postprocedural %DS in both treatment groups of
phase II. 
e579 lower in the direct stenting than in the predilatation
group (p = 0.0001 Wilcoxon; p < 0.0001 t-test) (Figure 3A).
Most of the cost saving calculated in the direct stenting
group was attributable to the reduced use of angioplasty
balloons (e463). At the time of discharge from the hospi-
tal, the average cost per patient was e3857 in the direct
stenting group, versus e4401 in the predilated group
(p = 0.0001 Wilcoxon; p < 0.001 t-test). Between discharge
of the patient from hospital and the end of follow-up, the
mean cost per patient was e182 higher in patients ran-
domized to direct stenting than to predilatation. The
higher costs in the direct stenting group during follow-up
were mostly attributable to the surgical and hospitaliza-
tion costs incurred by four patients undergoing coronary
artery bypass graft surgery, in contrast to a single patient in
the predilated group. At nine months, the overall cost per
patient was e6698 in patients randomized to direct stent-
ing versus e7060 in patients randomized to predilatation
(p = 0.0171 Wilcoxon; p = 0.5149 t-test). The absence of a
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significant difference by t-test was due to the wide disper-
sion in costs incurred in both groups during long-term
follow-up. The probability of direct stenting being more
effective and less costly was 31.5% while the probability of
stenting after predilatation being more effective and less
costly was 21.7% (Figure 3B).
Discussion
The sequential design of this study, which included a non-
randomized phase followed by a randomized phase,
allowed us to: (1) examine separately the six-month angio-
graphic outcomes of the direct stenting strategy, and (2)
compare separately its effects on clinical events and
medical costs up to nine months with a standard approach
of stenting preceded by predilatation, without the con-
founding influence of protocol-mandated follow-up
angiography. 
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Figure 2
(A) Kaplan-Meier survival free from target vessel revascularization in Phase II
of VELVET (B) Kaplan-Meier survival free from major adverse cardiac events
in Phase II of VELVET.
Figure 3
(A) Procedure-related cost-effectiveness analysis of direct stenting (DIR ST)
versus predilatation. Inner ellipse=5% probability; middle ellipse = 50%
probability; outer ellipse = 50% probability. (B) Cost-effectiveness analysis
of direct stenting versus predilatation up to 270 days.
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Safety and efficacy in phase 1
The non-randomized phase of VELVET confirmed that, in
properly selected patients, a primary delivery strategy
success rate in excess of 90% can be achieved with direct
stenting. The final procedural success rate, including the
few patients in whom balloon predilatation was needed,
was equivalent to that typically observed with standard
methods in this type of patient population. More impor-
tantly, there seemed to be no negative effect of direct stent-
ing on the long-term angiographic or clinical results in this
group of patients. The low six-month restenosis (11%) and
target lesion revascularization (6.6%) rates are particularly
noteworthy, and considerably below what was predicted
by multivariate analysis based on models derived from
comparable populations. In the absence of a clear explana-
tion for this unexpected result we can only hypothesize
that a somewhat skewed data distribution of the %DS at
follow-up in a relatively small sample size, with seven out
of 99 patients having a %DS between 45% and 49%, may
have yielded a lower than predicted six-month restenosis
rate. Had these patients been counted as cases of resteno-
sis, the rate would have been 17%. 
As typically seen in this type of analysis, postprocedural
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minimum luminal diameter and multiple stents were pre-
dictors of restenosis. Lesion eccentricity (type IIb of the
Ambrose classification),21 an angiographic marker of
higher instability, importantly emerged as an independent
risk factor for  major adverse cardiac events associated with
direct stenting. In contrast, unstable angina was associated
with a higher success rate of direct stenting, possibly owing
to a lower resistance to passage of the catheter offered by
unstable lesions.
Safety and efficacy in phase II
The primary success rate of the intended implantation
method was significantly higher in patients randomized to
predilatation than to direct stenting. However, the proce-
dural success rates of the two methods were similar, and
equivalent to the final success rate measured in phase I.
From the results of phases I and II, the incremental success
rate conferred by balloon predilatation is approximately
5%. As in phase I, rates of long-term major adverse cardiac
events were comparably low in both treatment groups in
phase II, confirming that a strategy of systematic direct
stenting with provisional predilatation is associated with
long-term results as favorable as those associated with a
systematic strategy of balloon predilatation. 
The entry criteria for this study, which was designed to
evaluate the application of direct coronary stenting in a
wide spectrum of lesions, were intentionally non-restric-
tive. No preprocedural angiographic characteristic was
retained as an independent predictor of success of delivery
strategy in the multivariate analysis, although moderate-
to-heavy calcification was a negative predictor in the uni-
variate analysis. 
Cost analysis
An expected advantage of direct coronary stenting, as
opposed to stenting after predilatation, is the use of fewer
balloon catheters and related devices, of smaller quantities
of contrast material, and a shorter stay in the catheteriza-
tion laboratory.22 This expectation has generally been con-
firmed in previous studies.1,3,6,9,11-17 However, the results of
formal cost analyses have been mixed. Except in one
study,16 procedural costs were only modestly reduced, as
was observed in this study.12,15 Furthermore, this study,
which was designed uniquely to compare costs in a popu-
lation whose long-term management is similar to standard
clinical practice, is the first to report results beyond the in-
hospital phase of the treatment. While a small advantage
persisted in favor of direct stenting at nine months, the dif-
ference was no longer significant due to the considerable
costs resulting from additional hospitalizations and proce-
dures during long-term follow-up, and increased variabil-
ity of costs among patients of both groups. 
In conclusion, in this selected patient population, stent
delivery preceded by balloon dilatation and direct coro-
nary stenting yielded similar overall procedural success
rates. When direct stenting failed, the intervention typ-
ically proceeded uneventfully with standard techniques,
including predilatation. The one-month rate of the com-
posite endpoint of ischemic symptoms and/or major
adverse cardiac events and cerebrovascular accidents, and
the nine-month major adverse cardiac event rates were
similar in both treatment groups. The procedural success
and major adverse cardiac events rates observed in the
non-randomized phase of the study were similar to those
measured in phase II. Finally, the significant cost saving
attributable to the direct stenting strategy that was evident
post procedure and after 30 days, was no longer significant
after nine months.
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Cost item Direct stenting Predilatation
Procedure time 1079 1159
Balloon catheter 133 596
Bx-Velocity™ stent 870 892
Guiding catheter 115 123
Guide wire 129 135
Contrast material 102 108
Non-study stent 7 7
Miscellaneous 86 80
PROCEDURAL COSTS 2521 3100*
Hospital costs 1336 1301
TOTAL IN-HOSPITAL COSTS 3857 4401**
Follow-up costs 2841 2659
OVERALL NINE-MONTH COSTS 6698 7060***
Values represent mean cost per patient (± SD) in Euros.  Mean procedure times were 59.3 min in the direct stenting group versus 63.8 min in the predilated group. 
*p < 0.0001; **p < 0.001; ***non-significant.
Table 5
Comparisons of procedural, hospitalization, and follow up costs in phase II of VELVET.
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